Emerging methods in colorectal cancer screening

Ryan, Éanna J; Creagh, Emma M.

doi:10.1002/bjs.10650

Cited by 5 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…circulating tumor DNA(ctDNA), abnormal DNA methylation, DNA mutations (such as KRAS, TP53, APC, BRAF), RNA markers, and soluble protein markers (CEA, CA199, etc.) have been gradually used for early screening and guiding the treatment of colorectal cancer [22][23][24][25][26].However, due to the low diagnostic e ciency and the cost of detection technology, it has not been widely used in clinical practice. Carcinoembryonic antigen(CEA), as a widely used marker in colon cancer screening and predicting recurrence, has a sensitivity of 30%-60% in the diagnosis of colon cancer, which is far from meeting the clinical expectations [27][28].…”

Section: Disscussionmentioning

confidence: 99%

Overexpression of COL4A1 promotes progression of colon cancer and is associated with poor prognosis

Li,

Wang,

Wang

2024

Preprint

View full text Add to dashboard Cite

Background Colon cancer is one of the common malignant tumor diseases of the digestive system, and its incidence and mortality rate are increasing year by year.Collagen type IV alpha 1 chain (COL4A1) is a hypoxia-associated gene (a collagen family protein) involved in the formation of the extracellular matrix.COL41 plays an important role in the progression of several cancers and is associated with poorer prognostic outcomes.However, whether it can mediate the progression of colon cancer is unclear. Method First, based on the TCGA-COAD dataset, we analyzed the mRNA expression levels of COL4A1 in colon cancer and evaluated the relationship between COL4A1 and clinicopathological features as well as prognosis.Then,we further analyzed the expression of COL4A1 in colon cancer tissues and colon tumor cells by qRT-PCR and HIC.Colon cancer cell lines SW480 and HCT116 were transfected with small interfering rna (siRNA) to construct low expression cell lines.Clone formation assay and transwell migration and invasion assays were used to detect the effects of knockdown of COL4A1 on proliferation, migration and invasion of colon cancer cells. Result Bioinformatics analysis showed that COL4A1 was significantly higher expressed in colon cancer tissues than in normal colon tissues. High expression of COL4A1 is associated with poor clinical stage and poor prognosis.We observed that COL4A1 was also highly expressed in colon cancer tissue and colon tumor cells compared with normal colon tissue and normal colon cells.Downregulation of COL4A1 significantly inhibited tumor cell proliferation, migration and invasion progression. Conclusion In summary, our study suggests that COL4A1 is a potential oncogene for colon cancer and can mediate colon cancer progression.

show abstract

Section: Disscussionmentioning

confidence: 99%

Overexpression of COL4A1 promotes progression of colon cancer and is associated with poor prognosis

Li,

Wang,

Wang

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…hepatitis, pancreatitis, obstructive pulmonary disease, and inflammatory bowel disease), and analytical variables such as variations in sampling and storage methods, patients' condition, and stability of the biomarkers [62,63]. Thus, the identification of a rapid, sensitive, and CRC marker-specific method is crucial in developing accurate assays for effective CRC detection from peripheral blood [64].…”

Section: Existing Blood-based Biomarkers Are Not Effective With Low Accuracymentioning

confidence: 99%

Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is ranked second for cancer-related deaths worldwide with approximately half of the patients being diagnosed at the late stages. The untimely detection of CRC results in advancement to the metastatic stage and nearly 90% of cancer-related deaths. The early detection of CRC is crucial to decrease its overall incidence and mortality rates. The recent introduction of circulating tumor cells (CTCs) has enabled a less invasive sampling method from liquid biopsies, besides revealing key information toward CRC metastasis. The current gold standard for CTC identification is the CellSearch® system (Veridex). This first-generation instrumentation relies on a single cell surface marker (CSM) to capture and count CTCs. Detection of CTCs allows the identification of patients at risk for metastasis, whereas CTC enumeration could improve risk assessment, monitoring of systemic therapy, and detection of therapy resistance in advanced metastatic CRC. In this review, we compared the pros and cons between single CSM-based CTC enrichment techniques and multi-marker-based systems. We also highlighted the challenges faced in the routine implementation of CSM-dependent CTC detection methods in CRC screening, prediction, prognosis, disease monitoring, and therapy selection toward precision medicine, as well as the dwelling on post-CTC analysis and characterization methods.

show abstract

“…In this regard, the U.S. Preventive Services Task Force (USPSTF) recommends regular screening using stool-based tests (including guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT) and multitargeted stool DNA test (FIT-DNA)), direct visualization tests (including colonoscopy, computed tomography (CT) colonoscopy and sigmoidoscopy), or serology tests (e.g., SEPT9 methylated DNA test), in adult aged 50 to 75 years (Ryan and Creagh, 2018). Among these screening tests, colonoscopy has the highest efficacy, but the invasive procedure can increase morbidity as well as induce psychological pain (Ryan and Creagh, 2018). Therefore, considerable effort is being made to identify novel cancer markers in biospecimens such as serum, plasma, and stool for the development of less invasive screening tests.…”

Section: Diagnostic Role Of Dna Methylation Markers In Oncologymentioning

confidence: 99%

Developing DNA methylation-based diagnostic biomarkers

Kim

Wang

Jin

2018

Journal of Genetics and Genomics

View full text Add to dashboard Cite

An emerging paradigm shift for disease diagnosis is to rely on molecular characterization beyond traditional clinical and symptom-based examinations. Although genetic alterations and transcription signature were first introduced as potential biomarkers, clinical implementations of these markers are limited due to low reproducibility and accuracy. Instead, epigenetic changes are considered as an alternative approach to disease diagnosis. Complex epigenetic regulation is required for normal biological functions and it has been shown that distinctive epigenetic disruptions could contribute to disease pathogenesis. Disease-specific epigenetic changes, especially DNA methylation, have been observed, suggesting its potential as disease biomarkers for diagnosis. In addition to specificity, the feasibility of detecting disease-associated methylation marks in the biological specimens collected noninvasively, such as blood samples, has driven the clinical studies to validate disease-specific DNA methylation changes as a diagnostic biomarker. Here, we highlight the advantages of DNA methylation signature for diagnosis in different diseases and discuss the statistical and technical challenges to be overcome before clinical implementation.

show abstract

Emerging methods in colorectal cancer screening

Abstract: Gene‐specific possibilities

Cited by 5 publications

References 22 publications

Overexpression of COL4A1 promotes progression of colon cancer and is associated with poor prognosis

Overexpression of COL4A1 promotes progression of colon cancer and is associated with poor prognosis

Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells

Developing DNA methylation-based diagnostic biomarkers

Contact Info

Product

Resources

About